WHO: BQ Scheme Can Align With FDA Suffix As Long As It Remains Random

The World Health Organization says there is a way to combine its newly unveiled biosimilar naming approach, which relies on biological qualifiers, with the divergent approach pushed by FDA: If a company is first provided an FDA suffix for their biological product, that code could be added to the Biological Qualifier database and then applied when a qualifier is requested for the same drug substance. Alliance for Safe Biologic Medicines Executive Director Michael Reilly says WHO is seeking as much...